{
    "nct_id": "NCT05403541",
    "official_title": "A Phase 3, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis (gMG)",
    "inclusion_criteria": "1. Are ≥ 18 years of age at the Screening Visit.\n2. Have mild to severe gMG by Myasthenia Gravis Foundation of America (MGFA) classification Class II, III, or IVa at the Screening Visit.\n3. Have a QMG score ≥ 11 at the Screening and Baseline Visits.\n4. Have a MG-ADL score of ≥ 5 at the Screening and Baseline Visits.\n5. Additional inclusion criteria are defined in the protocol.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Have experienced myasthenic crisis within 3 months of the Screening Visit.\n2. Have had a thymectomy performed < 6 months prior to the Screening Visit or have a planned thymectomy during the study period.\n3. Have any active or untreated malignant thymoma.\n4. Have received any agent or therapy (exclusive of those identified within inclusion criteria) with immunosuppressive properties (e.g., stem cell therapy, chemotherapies) within the past year.\n5. Have used anti-FcRn treatment within 3 months prior to the Screening Visit or have a documented history of non-response to prior anti-FcRn treatment.\n6. Additional exclusion criteria are defined in the protocol.",
    "miscellaneous_criteria": ""
}